[go: up one dir, main page]

PE20030037A1 - Derivados de cianoantranilamida como inhibidores de la tirosina cinasa - Google Patents

Derivados de cianoantranilamida como inhibidores de la tirosina cinasa

Info

Publication number
PE20030037A1
PE20030037A1 PE2002000386A PE2002000386A PE20030037A1 PE 20030037 A1 PE20030037 A1 PE 20030037A1 PE 2002000386 A PE2002000386 A PE 2002000386A PE 2002000386 A PE2002000386 A PE 2002000386A PE 20030037 A1 PE20030037 A1 PE 20030037A1
Authority
PE
Peru
Prior art keywords
alkyl
derivatives
cyanoantranilamide
inhibitors
tyrosine kinase
Prior art date
Application number
PE2002000386A
Other languages
English (en)
Inventor
Alexander Ernst
Martin Haberey
Karl-Heinz Thierauch
Martin Kruger
Andreas Menrad
Andreas Huth
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001123587 external-priority patent/DE10123587B4/de
Priority claimed from DE2001125295 external-priority patent/DE10125295A1/de
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20030037A1 publication Critical patent/PE20030037A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C04CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04BLIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632Organic additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)

Abstract

SE REFIERE A DERIVADOS DE CIANOANTRANILAMIDA DE FORMULA I DONDE A ES -N(R7)-; W ES O, S, H, -N(R8)-; Z ES UNA UNION, EL GRUPO -N(R10)-, =N-, ALQUILO C1-C12, ENTRE OTROS; X ES ALQUILO C1-C6; R1 ES ALQUILO C1-C12, ALQUENILO C2-C12, ENTRE OTROS; D ES UN ATOMO DE N, GRUPO C-R3; E ES N, C-R4; F ES N, C-R5; G ES C-R6 DONDE R3, R4, R5 Y R6 SON H, HALOGENO, ALCOXI C1-C6, ALQUILO C1-C6, CARBOXIALQUILO C1-C6, ENTRE OTROS; R7 ES H, ALQUILO C1-C6, ENRE OTROS; R9 Y R10 SON H, ALQUILO C1-C6. UN COMPUESTO PREFERIDO ES AMIDA DE ACIDO N-(ISOQUINOLIN-3-IL)-2-(4-(2-CIANOPIRIDILMETIL)AMINOBENZOICO. LOS DERIVADOS DE FORMULA I TIENEN ACTIVIDAD INHIBIDORES DE LA TIROSINA CINASA KDR Y FLT Y SON UTILES PARA EL TRATAMIENTO DE TUMORES
PE2002000386A 2001-05-08 2002-05-08 Derivados de cianoantranilamida como inhibidores de la tirosina cinasa PE20030037A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001123587 DE10123587B4 (de) 2001-05-08 2001-05-08 Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel
DE2001125295 DE10125295A1 (de) 2001-05-15 2001-05-15 Cyanoanthranylamid-Derivate und deren Verwendung als Arzneimittel (II)

Publications (1)

Publication Number Publication Date
PE20030037A1 true PE20030037A1 (es) 2003-02-05

Family

ID=26009296

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000386A PE20030037A1 (es) 2001-05-08 2002-05-08 Derivados de cianoantranilamida como inhibidores de la tirosina cinasa

Country Status (13)

Country Link
US (1) US7429592B2 (es)
EP (1) EP1387838B1 (es)
JP (1) JP4343681B2 (es)
AR (1) AR035879A1 (es)
AT (1) ATE323694T1 (es)
CY (1) CY1105140T1 (es)
DE (1) DE50206476D1 (es)
DK (1) DK1387838T3 (es)
ES (1) ES2261693T3 (es)
PE (1) PE20030037A1 (es)
PT (1) PT1387838E (es)
TW (1) TWI251593B (es)
WO (1) WO2003000678A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10023484A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
IL158783A0 (en) * 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
US7307088B2 (en) * 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) * 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) * 2003-06-13 2007-04-10 Schering Ag VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
US7906533B2 (en) * 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1657241A1 (en) * 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655297A1 (en) * 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
PA8840701A1 (es) 2008-08-27 2010-04-21 Leo Pharma As NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
EP2957283B1 (de) 2014-06-19 2022-12-21 Symrise AG Verfahren zur Identifizierung von Medikamenten zur Beschleunigung der Wundheilung
WO2022111793A1 (en) 2020-11-24 2022-06-02 Symrise Ag Medicament for accelerated wound healing
CN112675173B (zh) * 2020-12-25 2022-04-05 华南理工大学 FXIa抑制剂化合物或其盐的医药用途
WO2022161593A1 (en) 2021-01-26 2022-08-04 Symrise Ag Medicament for accelerated wound healing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6910994A (en) 1993-05-14 1994-12-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
DE19910396C2 (de) 1999-03-03 2001-12-13 Schering Ag Anthranilsäureamide und deren Verwendung als Arzneimittel
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use

Also Published As

Publication number Publication date
AR035879A1 (es) 2004-07-21
WO2003000678A1 (de) 2003-01-03
US7429592B2 (en) 2008-09-30
PT1387838E (pt) 2006-08-31
ATE323694T1 (de) 2006-05-15
EP1387838B1 (de) 2006-04-19
TWI251593B (en) 2006-03-21
DE50206476D1 (de) 2006-05-24
EP1387838A1 (de) 2004-02-11
US20040266770A1 (en) 2004-12-30
CY1105140T1 (el) 2010-03-03
DK1387838T3 (da) 2006-08-14
JP2004532281A (ja) 2004-10-21
JP4343681B2 (ja) 2009-10-14
ES2261693T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
PE20030037A1 (es) Derivados de cianoantranilamida como inhibidores de la tirosina cinasa
ATE297910T1 (de) Retinoid x rezeptormodulatoren
PE20021081A1 (es) Aril y biaril piperidinas con actividad moduladora mch
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
CY1108908T1 (el) Ενωσεις κινολινονης - καρβοξαμιδης ως αγωνιστες υποδοχεων 5-ητ4
EA201170096A1 (ru) Замещенные производные пиримидона
EA200700099A1 (ru) Производные пиридина
PE20021002A1 (es) Compuestos heterociclicos condensados
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
DE60210944D1 (de) N-substituierte heterocyclische nichtaryl-nmda/nr2b-antagonisten
PE20010070A1 (es) COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica
PE20040988A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20071080A1 (es) Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv
PE20030012A1 (es) Composicion y actividad antiviral de derivados de indoloxoacetico piperazina sustituidos
EA200300619A1 (ru) Серотонинергические средства
PE20030924A1 (es) Combinacion de inhibidores de ptm o inhibidores de la secrecion de apob con fibratos para la utilizacion como medicamentos
HRP20090264T1 (hr) Derivati fenil-piperazin metanona
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
EA201070813A1 (ru) Производные n-гетероциклоимидазо[1,2-а]пиридин-2-карбоксамидов, их получение и применение в терапии
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
ATE332695T1 (de) Pyrimidin-derivate als selektive inhibitoren von cox-2

Legal Events

Date Code Title Description
FC Refusal